Oxygenta Pharma Peer Comparison
BSE: 524636
₹53.05
₹-0.15
(-0.28%)
As on 21-Sep-2026 12:43IST
Market cap
₹187 Cr
Revenue (TTM)
₹135 Cr
P/E Ratio
--
P/B Ratio
-4.2
Div. Yield
0 %
Edit
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
187 | 35,679 | 28,799 | 28,679 | 28,038 |
Revenue (₹ Cr) |
135 | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
-13.58 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
-10.06 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
-- | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
-- | 87.24 | 99.92 | 74.25 | -- |
Price-To-Book |
-4.17 | 7.09 | 21.45 | 16.62 | 3.50 |
Income Statement (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
134.79 | 3,564.00 | 1,935.80 | 1,461.80 | 9,205.28 |
|
Total Income
|
134.98 | 3,686.00 | 1,948.58 | 1,489.25 | 9,449.59 |
|
Total Expenditure
|
142.83 | 2,792.00 | 1,485.56 | 919.25 | 8,195.15 |
|
EBITDA
|
-8.05 | 772.00 | 450.24 | 542.56 | 1,010.13 |
|
Depreciation
|
2.09 | 226.00 | 50.83 | 37.68 | 857.51 |
|
EBIT
|
-10.14 | 546.00 | 399.41 | 504.88 | 152.62 |
|
Interest
|
6.61 | 217.00 | 40.84 | 3.77 | 342.73 |
|
Other Income
|
0.20 | 122.00 | 12.78 | 27.45 | 244.31 |
|
Exceptional Items
|
0.00 | 12.00 | 0.00 | 0.00 | -216.88 |
|
Profit before Tax
|
-16.55 | 463.00 | 371.35 | 528.56 | -162.68 |
|
Provision for Tax
|
-2.97 | 49.00 | 83.14 | 141.21 | 209.13 |
|
Profit after Tax
|
-13.58 | 414.00 | 288.22 | 387.35 | -371.81 |
Liabilities (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-42.69 | 4,940.00 | 1,288.82 | 1,653.56 | 8,162.62 |
|
Minority Interest
|
0.00 | -5.00 | 0.00 | -1.13 | 0.00 |
|
Non-Current Liabilities
|
76.27 | 1,712.00 | 202.03 | 42.40 | 5,044.14 |
|
Current Liabilities
|
86.10 | 1,622.00 | 835.87 | 230.82 | 4,758.28 |
|
Total Liabilities
|
119.68 | 8,578.00 | 2,326.71 | 1,983.96 | 17,723.32 |
Assets (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
65.48 | 5,343.00 | 519.60 | 1,026.85 | 10,211.52 |
|
Current Assets
|
51.43 | 2,606.00 | 1,681.81 | 881.27 | 7,191.66 |
|
Total Assets
|
119.68 | 8,578.00 | 2,326.71 | 1,983.96 | 17,723.32 |
|
Total Debt*
|
109.57 | 2,125.00 | 259.37 | 26.49 | 5,495.48 |
|
Net Current Assets
|
-34.67 | 984.00 | 845.94 | 650.46 | 2,433.38 |
|
Contingent Liabilities
|
0.17 | 768.26 | 19.09 | 17.25 | 95.72 |
Cashflow (₹ Cr)
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-27.75 | 390.00 | 205.05 | 292.17 | 1,652.60 |
|
Cash Flow from Investing Activities
|
-14.39 | -241.00 | -409.72 | -265.94 | -826.03 |
|
Cash from Financing Activities
|
42.56 | -54.00 | 283.07 | 4.10 | -38.98 |
|
Net Cash Inflow / Outflow
|
0.42 | 95.00 | 78.39 | 30.33 | 787.59 |
Ratios
Profitability Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-33.53 | 6.79 | 29.22 | 32.42 | 1.24 |
|
ROE (%)
|
0.00 | 8.38 | 29.77 | 25.18 | -3.85 |
|
ROA (%)
|
-13.41 | 4.94 | 24.77 | 21.93 | -2.21 |
|
EBIT Margin (%)
|
-7.52 | 15.32 | 20.63 | 34.54 | 1.66 |
|
Net Margin (%)
|
-10.06 | 11.23 | 14.79 | 26.01 | -3.93 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
19.23 | 18.37 | 46.65 | 40.90 | 0.78 |
|
EBIT Growth (%)
|
36.85 | 252.26 | 62.13 | 124.50 | -70.53 |
|
Net Profit Growth (%)
|
9.71 | 377.85 | 89.49 | 104.15 | -1,383.43 |
|
EPS Growth (%)
|
10.38 | 1,001.33 | 78.60 | 42.32 | -484.84 |
|
Book Value Growth (%)
|
-66.48 | 13.47 | 144.31 | 26.03 | 0.33 |
Valuation Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-14.49 | 85.10 | 99.18 | 72.88 | -88.50 |
|
Price / Book Value
|
-4.39 | 6.74 | 21.63 | 16.31 | 3.46 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.09 | 0.07 | 0.00 |
|
EV/EBITDA
|
-37.80 | 45.82 | 64.29 | 51.52 | 31.51 |
|
Market Cap (₹ Cr)
|
178.93 | 19,071.62 | 12,753.19 | 20,944.75 | 18,108.89 |
Solvency Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.76 | 0.31 | 0.11 | 0.02 | 0.53 |
|
Short term debt to equity ratio
|
-0.74 | 0.09 | 0.05 | 0.02 | 0.09 |
|
Current Ratio
|
0.60 | 1.61 | 2.01 | 3.82 | 1.51 |
|
Quick Ratio
|
0.26 | 1.06 | 1.14 | 2.82 | 0.87 |
|
Interest Coverage
|
-1.50 | 3.13 | 10.09 | 141.16 | 0.53 |
Operating Efficiency Ratios
| Oxygenta Pharma | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
7.44 | 16.50 | 26.28 | 24.80 | 23.44 |
|
Asset Turnover
|
1.33 | 0.43 | 1.66 | 0.83 | 0.55 |
|
Receivable days
|
24.43 | 58.75 | 40.13 | 88.98 | 78.20 |
|
Inventory Days
|
80.66 | 75.82 | 60.29 | 56.04 | 93.30 |
|
Payable days
|
140.38 | 186.21 | 232.47 | 99.95 | 226.14 |
|
Cash Conversion Cycle
|
-35.29 | -51.64 | -132.04 | 45.07 | -54.64 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
